Medical AI Alliance
← Company Index
Medical DevicesKOSDAQ 21445062 approvals

PharmaResearch Co., Ltd.

Official website

KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.

As of 2026-10-10, PharmaResearch Co., Ltd. has 43 Korean MFDS device approvals, 19 Korean MFDS drug approvals, 4 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2001 and listed on KOSDAQ in 2015, PharmaResearch is a medical device company. It produces pharmaceuticals (Placentex, Rejuvinex, Zadaxin, Reentox), medical devices (HA fillers Cleviel and Rejuviel, PN-type Rejuran and Conjuran), and Rejuran-branded cosmetics (Healer, Clinic, and Derma Healer lines). Revenue is split 58.6% medical devices, 24.6% cosmetics, 15.4% pharmaceuticals, and 1.4% other, manufactured at Gangneung Plant 1 and 2 and subsidiary PharmaResearch Bio's dedicated botulinum toxin facility.

Products & technology

  • PlacentexPDRN pharmaceutical
  • RejuvinexPDRN pharmaceutical
  • Zadaxinimmune enhancer
  • Reentoxbotulinum toxin
  • Clevielfacial aesthetic HA filler
  • Rejuvielfacial aesthetic HA filler
  • RejuranPN-type facial aesthetic injection
  • ConjuranPN-type intra-articular knee injection

Regulatory approvals

data.go.kr

19 Korean MFDS drug approvals · 2000–2025 / 43 Korean MFDS device approvals · 1999–2026

  • MFDSDressing, occlusive, hydrogel2026-08-21
    Product approval · Class 2제인 26-4774 호
  • MFDSGraft/prosthesis, biomaterial2026-08-20
    Product approval · Class 4제허 26-637 호
  • MFDSDressing, fluid-impermeable film2026-05-04
    Product approval · Class 2제인 26-4393 호
  • MFDSGraft/prosthesis, biomaterial2026-03-06
    Product approval · Class 4제허 26-180 호
  • MFDSDressing, fluid-impermeable film2026-01-28
    Product approval · Class 2제인 26-4088 호
  • MFDSDressing, fluid-impermeable film2025-08-27
    Product approval · Class 2제인 25-4792 호
  • MFDS drugTeriment Injection(Teriparatide)2025-07-17
    Drug · Prescription · Approval202501822
  • MFDSGraft/prosthesis2024-12-03
    Product approval · Class 4제허 24-853 호
  • MFDSGraft/prosthesis, biomaterial2024-11-04
    Product approval · Class 4제허 24-767 호
  • MFDSGraft/prosthesis2024-11-04
    Product approval · Class 4제허 24-766 호
  • MFDSDressing, fluid-impermeable film2024-07-25
    Product approval · Class 2제인 24-720 호
  • MFDSGraft/prosthesis, biomaterial2024-01-25
    Product approval · Class 4제허 24-65 호
Show 50 more
  • MFDSGraft/prosthesis, biomaterial2023-02-06
    Product approval · Class 4제허 23-81 호
  • MFDSGraft/prosthesis, biomaterial2022-11-18
    Product approval · Class 4제허 22-777 호
  • MFDS drugPR-cholecalciferol inj2021-10-13
    Drug · Prescription · Notification202106881
  • MFDS drugPR-Tramadol Hydrochloride Inj.Revoked2021-08-31
    Drug · Prescription · Notification202106253
  • MFDS drugPR-Diclofenac Sodium Inj.Revoked2021-08-30
    Drug · Prescription · Notification202106241
  • MFDSDressing, fluid-impermeable film2021-08-24
    Product approval · Class 2제인 21-4736 호
  • MFDS drugPR-magnesium sulfate heptahydrate Inj. 100mgRevoked2021-08-18
    Drug · Prescription · Notification202106007
  • MFDS drugPR-thioctic acid Inj. 5mgRevoked2021-08-11
    Drug · Prescription · Notification202105901
  • MFDSGraft/prosthesis, biomaterial2021-07-23
    Product approval · Class 4제허 21-629 호
  • MFDS drugPR-ascorbic acid Inj. 500mgRevoked2021-07-13
    Drug · Prescription · Notification202105322
  • MFDS drugPR-fursultiamine injRevoked2021-03-25
    Drug · Prescription · Notification202102613
  • MFDSDressing, adhesion barrier2021-03-03
    Product approval · Class 3제허 21-162 호
  • MFDS drugNew-ARTI Inj.2020-03-16
    Drug · Prescription · Notification202001796
  • MFDSDressing, fluid-impermeable filmRevoked2019-10-07
    Product approval · Class 2제인 19-4830 호
  • MFDSGraft/prosthesis, biomaterial2019-06-12
    Product approval · Class 4제허 19-366 호
  • MFDSGraft/prosthesis, biomaterial2017-10-25
    Product approval · Class 4제허 17-814 호
  • MFDSGraft/prosthesis, biomaterial2017-05-29
    Product approval · Class 4제허 17-353 호
  • MFDSGraft/prosthesis, biomaterial2017-05-10
    Product approval · Class 4수허 17-227 호
  • MFDSGraft/prosthesis, biomaterial2016-11-11
    Product approval · Class 4제허 16-826 호
  • MFDSGraft/prosthesis, biomaterial2016-03-24
    Product approval · Class 4제허 16-217 호
  • MFDS drugRe-an Eye Drops (Polydeoxyribonucleotide sodium) (single use)2015-06-26
    Drug · OTC · Approval201504166
  • MFDSGraft/prosthesis, biomaterial2015-01-20
    Product approval · Class 4제허 15-83 호
  • MFDS drugRejuvenex Inj.(Polydeoxyribonucleotide sodium)2015-01-07
    Drug · Prescription · Approval201500071
  • MFDS drugRejuvenex Cream(Polydeoxyribonucleotide sodium)2014-12-05
    Drug · OTC · Notification201405771
  • MFDS drugPR-Purified Water2014-11-12
    Drug · OTC · Notification201405289
  • MFDSGraft/prosthesis, biomaterial2014-04-09
    Product approval · Class 4제허 14-825 호
  • MFDSGraft/prosthesis, biomaterial2014-01-07
    Product approval · Class 4제허 14-64 호
  • MFDS drugLaennec PO(Human Placenta Hydrolysate)2013-11-13
    Drug · OTC · Approval201310120
  • MFDSGraft/prosthesis, biomaterial2013-11-07
    Product approval · Class 4제허 13-1891 호
  • MFDSPolydioxanone suture2013-10-24
    Product approval · Class 4제허 13-1799 호
  • MFDSThread for facial tissue fixation, absorbable or non-absorbableRevoked2009-12-03
    Product approval · Class 4수허 09-1257 호
  • MFDS drugPLACENTEX INJ2008-09-04
    Drug · Prescription · Approval200809246
  • MFDS drugDuocaine cream2008-01-30
    Drug · Prescription · Notification200801307
  • MFDS drugJBP Plamon Inj.(Human Placenta Extract)2007-07-26
    Drug · Prescription · Approval200708605
  • MFDS drugVitafant Inj. 50(Fursultiamine Hydrochloride)Revoked2007-04-30
    Drug · Prescription · Notification200704948
  • MFDSNebulizing system, non-heatedRevoked2007-04-06
    Product approval · Class 2수허 07-301 호
  • MFDSNebulizing system, non-heatedRevoked2007-04-06
    Product approval · Class 2수허 07-300 호
  • MFDS혈압계Revoked2004-05-11
    Product approval · Class 2수허 04-619 호
  • MFDS의료용흡입기Revoked2003-06-10
    Product approval · Class 2수허 03-700 호
  • MFDS의료용흡인기Revoked2002-08-05
    Product approval · Class 2수허 02-864 호
  • MFDS혈압계Revoked2002-06-17
    Product approval · Class 2수허 02-673 호
  • MFDS의료용흡입기Revoked2001-11-16
    Product approval · Class 2수허 01-1384 호
  • MFDS의료용흡입기Revoked2001-11-16
    Product approval · Class 2수허 01-1385 호
  • MFDS의료용흡입기Revoked2001-11-16
    Product approval · Class 2수허 01-1386 호
  • MFDS의료용흡입기Revoked2001-11-15
    Product approval · Class 2수허 01-1372 호
  • MFDS개인용저주파자극기Revoked2001-11-15
    Product approval · Class 2수허 01-1373 호
  • MFDSMarker, surgical, internalRevoked2001-11-05
    Product approval · Class 2수허 01-1304 호
  • MFDS혈압계Revoked2001-10-24
    Product approval · Class 2수허 01-1263 호
  • MFDS drugZadaxin Inj2000-10-18
    Drug · Prescription · Approval200009072
  • MFDS이식형스태플 [2]Revoked1999-10-11
    Product approval · Class 1수신 99-3776 호

Global clinical trials

ClinicalTrials.gov · sponsor-matched

Key disclosures

KRX KIND via OpenDART

Publications

PubMed · affiliation-matched

Patents

KIPRIS · applicant-matched
Show 55 more patents

AI reads

MAA server logs · IP-verified
163
Times AI engines pulled PharmaResearch Co., Ltd.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

6
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

157
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

13
live 2
Last 7 days
122
live 5
Last 30 days
163
live 6
All time
  • OpenAIChatGPT-Userlive6
  • OpenAIOAI-SearchBot131
  • GoogleGoogleOther18
  • PerplexityPerplexityBot4
  • MicrosoftBingbot2
  • AnthropicClaudeBot2

Measured since Aug 25, 2026 · 5 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for PharmaResearch Co., Ltd. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · R&D. Send us materials and we will add them

Companies approved for the same productsMedical Devices

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

DongBang Medical Co., Ltd.6 shared

KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.

HANS BIOMED CORPORATION5 shared

KOSDAQ-listed medical device company producing human tissue implants Bella Cell HD and SureFuse.

JETEMA Co.,Ltd.5 shared

Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.

DongKookPharmaceuticalCo.,Ltd.5 shared

KOSDAQ-listed comprehensive healthcare and pharmaceutical company behind the gum treatment Insadol and the wound-care ointment Madecassol.

Chabiotech Co.,Ltd.4 shared

Cord blood storage and cell therapy company that has expanded into global CDMO manufacturing and overseas medical network services.

Humedix Co., Ltd.4 shared

KOSDAQ-listed aesthetics and CMO company behind the Elravie/Revolax hyaluronic-acid fillers and Leedstox botulinum toxin.

BNC KOREA, Inc.4 shared

Founded and listed on the KOSDAQ in 2016, BNC Korea is a biohealthcare company specializing in HA fillers, botulinum toxin, and dermo-cosmetics.

BioPlus Co., Ltd3 shared

Founded in 2003 and KOSDAQ-listed in 2021, BioPlus develops HA-based bio medical devices and biopharmaceuticals using its proprietary MDM Technology platform.

GC Medical Science Corporation3 shared

GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.

METABIOMED.CO.,LTD3 shared

KOSDAQ-listed medical device company manufacturing synthetic bioresorbable suture yarn and dental root canal filling materials.

Wonbiogen Co.,Ltd.3 shared

Wonbiogen Co.,Ltd., established September 2018, listed on KOSDAQ in December 2018, manufactures wound dressings and moist wound dressings.

JW PHARMACEUTICAL3 shared

Founded in 1945, JW Pharmaceutical holds an original drug pipeline including Rivalo and Hemlibra, plus the IV nutrition product Winuf and OTC brand Hwakol.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition